CYTK May 2019 6.000 put

OPR - OPR Delayed Price. Currency in USD
0.1300
0.0000 (0.00%)
As of 3:15PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1300
Open0.1300
Bid0.0000
Ask0.2500
Strike6.00
Expire Date2019-05-17
Day's Range0.1300 - 0.1300
Contract RangeN/A
Volume20
Open Interest24
  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Cytokinetics Inc Earnings Call

  • Cytokinetics Inc (CYTK) Q1 2019 Earnings Call Transcript
    Motley Fool10 days ago

    Cytokinetics Inc (CYTK) Q1 2019 Earnings Call Transcript

    CYTK earnings call for the period ending March 31, 2019.

  • Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
    Zacks10 days ago

    Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

    Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press10 days ago

    Cytokinetics: 1Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 54 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Cytokinetics shares have increased ...

  • GlobeNewswire10 days ago

    Cytokinetics Reports First Quarter 2019 Financial Results

    GALACTIC-HF Continues Following Interim Analysis for Futility; METEORIC-HF Opened to Enrollment Phase 1 Data for CK-274 Expected in Q3 2019; Planning Underway for Potential.

  • GlobeNewswire11 days ago

    Cytokinetics to Hold Annual Meeting of Stockholders

    Cytokinetics, Incorporated (CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2019 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.

  • Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters
    American City Business Journals13 days ago

    Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters

    The South San Francisco company says its mid-stage study was one of the best for people with ALS; investors initially were skeptical.

  • MarketWatch13 days ago

    Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints

    Shares of biotech Cytokinetics Inc. plunged 19% in premarket trade Monday after the company announced that a Phase 2 study of its amyotrophic lateral sclerosis drug did not show a meaningful difference in respiratory function, muscle strength or daily living measures compared with placebo. After 12 weeks on the drug, called reldesemtiv, patients did not show a statistically-significant difference in symptoms at three different dosage points when compared with patients on a placebo, though a post-hoc analysis grouping all treatment groups together showed improvement in daily living compared with placebo. Shares of Cytokinetics have gained 40% in the year to date, while the S&P 500 has gained 17.5%.

  • GlobeNewswire14 days ago

    Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting

    Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that results of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS) were presented today by Jeremy Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the University of Arizona, Phoenix, at a podium presentation at the American Academy of Neurology Annual Meeting in Philadelphia. FORTITUDE-ALS did not achieve statistical significance for a pre-specified dose-response relationship in its primary endpoint of change from baseline in slow vital capacity (SVC) after 12 weeks of dosing (p=0.11).

  • Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
    Zacks17 days ago

    Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire24 days ago

    Cytokinetics to Announce First Quarter Results on May 9, 2019

    Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report first quarter results on May 9, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.

  • What Are Analysts Expecting From Cytokinetics, Incorporated (NASDAQ:CYTK) In The Next Couple Of Years?
    Simply Wall St.24 days ago

    What Are Analysts Expecting From Cytokinetics, Incorporated (NASDAQ:CYTK) In The Next Couple Of Years?

    Cytokinetics, Incorporated's (NASDAQ:CYTK) released its most recent earnings update in December 2018, which signalled company earnings became less negative compared to the previous year's level as a...

  • Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know
    Zackslast month

    Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Cytokinetics to Present at April Investor Conferences

    The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights International Paper, Square, Sealed Air, Calix, e.l.f. Beauty, and Cytokinetics — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
    Zacks2 months ago

    Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

    Key highlights of the past week are multiple study failures and other pipeline updates.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...

  • Here's Why Cytokinetics Stock Jumped Today
    Motley Fool2 months ago

    Here's Why Cytokinetics Stock Jumped Today

    The clinical-stage biotech's long-running partnership with Amgen took another big step forward.

  • GlobeNewswire2 months ago

    Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

    Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct. The futility analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial’s protocol.

  • PR Newswire2 months ago

    Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

    THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The futility analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial's protocol.

  • GlobeNewswire2 months ago

    Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

    Cytokinetics, Incorporated (CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by John Teerlink, M.D., Professor of Clinical Medicine, University of California San Francisco and Director of Heart Failure, San Francisco Veterans Affairs Medical Center, in a Moderated Poster Session at the American College of Cardiology’s 68th Annual Scientific Session (ACC.19) in New Orleans.

  • GlobeNewswire2 months ago

    Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19

    SOUTH SAN FRANCISCO, Calif., March 11, 2019 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CYTK earnings conference call or presentation 21-Feb-19 9:30pm GMT

    Q4 2018 Cytokinetics Inc Earnings Call

  • GlobeNewswire2 months ago

    Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting

    Cytokinetics, Incorporated (CYTK) today announced that results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), will be presented in a platform presentation at the American Academy of Neurology 71st Annual Meeting in Philadelphia on Sunday, May 5, 2019. FORTITUDE-ALS is designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv (formerly CK-2127107). In collaboration with Astellas Pharma Inc. (Astellas), Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), as a potential treatment for people living with debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • Some Cytokinetics Shareholders Are Down 43%
    Simply Wall St.2 months ago

    Some Cytokinetics Shareholders Are Down 43%

    The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame longRead More...